EFFICACY OF LAMOTRIGINE IN DISABLING MYOCLONUS IN A PATIENT WITH AN mtDNA A3243G MUTATION
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Mitochondrial disorders may be associated with symptomatic myoclonus. Myoclonus is a cardinal feature of the progressive myoclonus epilepsy syndromes (PMEs), recognized causes of which are the mitochondrial disorders myoclonic epilepsy with ragged red fibers (MERRF) and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). MELAS presents with normal early development, stroke-like episodes at a young age, encephalopathy, epilepsy, cognitive decline, lactic acidosis, and ragged-red fibers on skeletal muscle biopsy. Myoclonus and partial seizures are common but variable clinical features.1 Presently, the treatment of myoclonus and epilepsy in the setting of MELAS and MERRF and other nonsyndromic mitochondrial disorders is empiric and largely based on anecdotal experience. There are no published reports on the use of lamotrigine in these mitochondrial disorders. The mechanism of action of lamotrigine is incompletely understood but, in part, is thought to interact with voltage-gated sodium channels leading to modification of ion fluxes. In this report, we describe the enduring abolition of disabling myoclonus in a patient …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.